Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine_Dosage, benefits & legal status
Also known as Palmitoyl Dipeptide-5 Diaminobutyloyl Hydroxythreonine, palmitoyl dipeptide 5 diaminobutyroyl hydroxythreonine
One of a pair, and the pair is the product.
What is Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine?
Plain language first. The technical label stays, but it never stands alone.Overview
Half of a two-peptide firming ingredient, never sold by itself.
A palmitoylated dipeptide carrying diaminobutyroyl and hydroxythreonine groups, supplied only as half of a patented two-peptide complex aimed at dermal-epidermal junction proteins.
What it's used for
A topical firming peptide used in anti-aging serums and creams, always alongside its partner peptide.
How does Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine work?
What it does in the body, and where.Skin is two layers glued together. The join, called the dermal-epidermal junction, is not flat: it folds into interlocking ridges, and those folds are what stop the surface shearing away and what let nutrients pass between layers. With age the folds flatten. The claim behind this ingredient is that flattening can be slowed by feeding the proteins that build the join.
- 01The fatty tail is what gets it inA short peptide with charged groups will not cross the outer layer of skin on its own. Attaching a 16-carbon palmitic acid chain trades water solubility for the ability to pass a lipid barrier. It is the same modification used on Matrixyl and on the other palmitoylated peptides in this library.
- 02The targets are named, which is unusualThe supplier names specific proteins: laminin V, collagens IV, VII and XVII, and integrin beta 4. Those are the actual anchoring proteins of the junction, including the components of hemidesmosomes, the rivets that pin basal cells to the membrane below. A claim this specific is at least checkable in principle, which is more than most cosmetic peptide claims offer.
- 03But it was never tested aloneThe supplier calls the ingredient a specific, patented combination of two highly active synthetic peptides, and that is how it is sold, formulated and tested. There is no published experiment separating this peptide's contribution from its partner's, so the division of labor between them is undocumented.
- 04What is claimed for the pairImproved elasticity, firmness and suppleness, with the supplier stating that skin tonicity, firmness and suppleness improve after about two months. Those are supplier figures for the complete material in a formula, with no control arm named in the material read here.

What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Skin conditioning, the function the cosmetic ingredient inventory assigns itnone
- Boosting dermal-epidermal junction proteins, the claim the supplier makes for the pairnone
- Elasticity, firmness and suppleness, from the supplier's own testing of the complete materialnone
The published record
0
Papers about Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine · this compound only
Searched: Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine, Palmitoyl Dipeptide-5 Diaminobutyloyl Hydroxythreonine.
Left out: SYN-TACKS (the trade name of the two-peptide material, not of this molecule); Palmitoyl Dipeptide-5 Diaminohydroxybutyrate (the partner peptide it is supplied with, which has its own page); Dipeptide-5 (the core shared by both peptides' names); 883558-32-5 (the CAS number, which does not appear in titles or abstracts); laminin (a protein named in the supplier's claim, with a large literature of its own); integrin (another such protein family, with a larger one still); dermal-epidermal junction (a general skin anatomy term); hemidesmosome (a cell structure named in the claim, with a literature of its own).
Europe PMC was searched on November 22, 2026 for these terms and returned nothing.
Counted from Europe PMC indexing, not read by a person.

At a glance
Four things to know about Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine
Evidence
Cosmetic
Category
Skin and cosmetic
Common vial
Varies
Half-life
Not measured, and not the right question
How much, and do you cycle it?
The range, and whether you take breaks.Set by the finished product, daily, as directed by the product. Not cycled Community practice
Used daily as part of a routine. Nothing about it suggests tolerance or a need for a break, and nothing has been studied that would show either way.
Not measured, and not the right questionNo figure
No half-life has been published. It is applied to the skin in a finished cosmetic rather than dosed into the bloodstream, so a circulating half-life would not describe anything useful. The relevant question for a lipidated topical peptide is how much penetrates and how long it persists in the tissue, and that has not been published for this one.
You can compare this against the whole library to see where it sits.
How is it given?
Dosing context and source notes.Supplied as a ready-made solution, so there is nothing to mix.
The supplier's own formulation guidelines give this peptide a use range of 0.1 to 1 percent within the trade material, and recommend the complete material at 1 percent of a skin care formula. Those are two different numbers describing two different things, which is the usual confusion with blended cosmetic actives: 1 percent of the material does not mean 1 percent of this peptide. No use level has ever been published for this peptide applied on its own, because it is not sold on its own.
How do you store it?
Before mixing, and after.Room temperature, out of light. Cap it tight after each use.
Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine ships as a cream, gel, or serum. Keep it at room temperature away from sun and heat unless the label says otherwise. Refrigerating an emulsion can split the texture. Watch for color, smell, or separation changes and stop using it if any appear.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- A known allergy to this ingredient or to others in the same product
- Broken, cracked, or actively irritated skin
- Reading a claim made for the two-peptide complex as a claim about this molecule
Stop and get help
- A rash that spreads beyond where you applied it
- Swelling of the face, lips, or eyelids, or any trouble breathing
- Burning that does not settle after rinsing it off
Common effects
- No adverse effects are reported for the isolated peptide, and no published testing has looked for them.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine approved?
And where the numbers on this page come from.Not as a medicine. Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine is sold without a prescription as a cosmetic ingredient, which is a different thing from being approved as a drug.
- Approval statusCosmeticSold without a prescription as an ingredient in cosmetics, such as skincare and hair products. The FDA does not approve cosmetics before they are sold, and being easy to buy says nothing about whether it works.
- RouteOn the skin (topical)
- Checked21 November 2026
- DoseNo dose has been established in people.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
What else is like Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine?
Others in Skin and cosmetic, side by side.If you're weighing Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine, it's worth reading Palmitoyl Dipeptide-5 Diaminohydroxybutyrate, Palmitoyl Hexapeptide-12, and Palmitoyl Hexapeptide-19 (BoNT-L Peptide) in the same class.
One of a pair, and the pair is the product.
- Dose
- Set by the finished product
- How often
- Daily, as directed by the product
The other half of the pair, and the one with the name problem.
- Dose
- Set by the finished product
- How often
- Daily, as directed by the product
Pal-VGVAPG, one of the two original palmitoyl peptides Sederma launched in 1992. Judged safe as used in cosmetics; the firming evidence is thin.
- Dose
- A few ppm in the finished product (up to 0.002%)
- How often
- Daily
A Botox-like cosmetic peptide whose published evidence is 15 volunteers and a supplier's own testing.
- Dose
- Set by the finished product
- How often
- Daily, as directed by the product
Guides for this compound
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- dsm-firmenich, SYN-TACKS formulation guidelines(2013)The supplier's own formulation guidelines, which is where both CAS numbers in this batch come from rather than from an aggregator. It gives Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine at a use range of 0.1 to 1 percent with CAS 883558-32-5, and Palmitoyl Dipeptide-5 Diaminohydroxybutyrate at 0.1 to 1 percent with CAS 794590-34-4. It recommends a concentration of 1 percent of the complete material for skin care preparations, gives storage at 2 to 8 degrees Celsius, and states that the combination of two peptides offers for the first time the possibility to interact with the most relevant protein structures of the dermal-epidermal junction: laminin V, collagen types IV, VII and XVII, and integrin.
- dsm-firmenich, SYN-TACKS CB product page(2026)The supplier's current product page, read at source for the active INCI names and the claim in the supplier's own wording. It gives the active INCI as Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine and Palmitoyl Dipeptide-5 Diaminohydroxybutyrate, describes the ingredient as a specific, patented combination of two highly active synthetic peptides, and states that it increases elasticity, firmness and suppleness by boosting the function of the dermal-epidermal junction, which it says restores junction function by boosting the synthesis of hemidesmosomal proteins.
- Ingredient industry listing, SYN-TACKS CB, full declared composition(2026)An ingredient industry listing for the same material, read as independent confirmation of the full declared composition and the formulator-facing claims. It gives the INCI as Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine and Palmitoyl Dipeptide-5 Diaminohydroxybutyrate and Glycerin and Aqua, describes the material as a patented peptide complex free of trifluoroacetic acid that contains no preservatives, and states that it helps improve skin tonicity, firmness and suppleness after only two months.
- Ingredient marketplace technical data sheet, SYN-TACKS(2026)A distributor technical data sheet, read for the protein targets stated independently of the supplier's own page. It describes the material as a patented combination of two highly active synthetic peptides that stimulates laminin V, collagens IV, VII and XVII and integrin beta 4, and says it improves anisotropy, molecular communication, structural integrity, skin tonicity, nutrient exchange, firmness and suppleness.
